Attenuation of canine atopic dermatitis pruritus through a novel complementary feed

Abstract

Canine atopic dermatitis (cAD) is a complex and multifaceted disease in which pruritus represents the main concern for owners. In recent years, non-pharmacological therapeutic alternatives for the long-term management of dermatological disorders and related symptoms are being explored. The aim of the present study was to assess the aptitude of a novel complementary feed containing bioactive molecules such as flavonoids, stilbenes and cannabinoids in the control of pruritus in cAD. Twelve dogs affected by cAD received oclacitinib for six weeks followed by supplementation with a complementary feed for 24 weeks. Canine Atopic Dermatitis Extent and Severity Index (CADESI-4) and Pruritus Visual Analogue Scale (PVAS) scores were recorded every two weeks for 28 weeks in total. Results obtained showed a statistically significant decrease of pruritus after treatment with oclacitinib in the first four weeks (oclacitinib discontinued at week six) and was maintained by complementary feed supplementation for six months. The data obtained suggest that the investigated complementary feed may help to control itching caused by cAD after an adequate period of oclacitinib administration.